ClinicalTrials.gg
CompletedNCT01218204Updated Jul 16, 2019Results posted

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

A Phase 2 interventional study of 10mg atorvastatin and 80mg atorvastatin in Dyslipidaemias and Dyslipidemias, sponsored by GlaxoSmithKline. Completed at 21 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-07-16.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
287
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing atorvastatin in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Dyslipidemias.

Enrollment
16th of 47
287 · median 165
Started
2010
with 2 others
Phase 2
8 of 47
none open now
Registered
24th of 47
by date

Among the 47 studies testing atorvastatin in Dyslipidemias, this one is the 16th largest by enrollment, is one of 3 that started in 2010, is one of 8 in phase 2, and was the 24th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

1 of the 47 studies testing atorvastatin in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing atorvastatin in Dyslipidemias, or all of them as a file.
02

Study summary

This study investigates the safety, pharmacokinetics and effects of GSK1292263 when taken alone or when co-dosed with atorvastatin to subjects with dyslipidemia.

Read the detailed description

This compound has been studied in healthy subjects and subjects with type II diabetes and is now being studied in subjects with dyslipidemia. Because many patients with dyslipidemia are on statins, it is important to study how GSK1292263 behaves when taken with a potent statin, atorvastatin. The cholesterol lowering drug, ezetimibe, is included for comparison.

03

Conditions studied

  • Dyslipidaemias
  • Dyslipidemias

Browse trials for

Keywords

  • Pharmacodynamics
  • Lipids
  • Dyslipidemia
  • Safety
  • GSK1292263
  • Ezetimibe
  • Statin
  • Pharmacokinetics
  • Tolerability
  • Atorvastatin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult males and females of non-child-bearing-potential, aged 18-75 years who is capable of giving .
  • A female subject is eligible to participate if she is of:

    • Non- defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or defined as 12 months of spontaneous amenorrhea. In questionable cases, a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol \<40 pg/ml (\<140 pmol/L) is confirmatory in the absence of a clear post-menopausal history.
    • Females on hormone replacement therapy (HRT) must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study.
  • Male subjects must agree to use one of the methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until seven days following the last dose.
  • Body weight > 50 kg (110 pounds) and (BMI) between 19.0 and 39.0 (inclusive).
  • Part A: (i) Subjects who are on 80mg or 40mg atorvastatin for >= 4 weeks and are tolerating the drug well, or (ii) Subjects not on lipid-modifying therapy who have a fasting low density lipoprotein cholesterol (LDLc) >= 130mg/dL.
  • In Part B at Screening: Subjects who are on statins or Vytorin treatment for >= 4 weeks.
  • Part B at the end of the 4 week washout: Subjects who have a fasting LDL cholesterol of >=120mg/dL and \<=180mg/dL and fasting triglycerides of >=100mg/dL and \<=400mg/dL.
  • Part B at the end of the 4 week run-in on atorvastatin: Subjects who are tolerating well atorvastatin 10mg or 80mg (as determined by the Investigator).
  • Part B: Subjects must be willing to discontinue statins or Vytorin for the duration of the study.
  • Liver enzymes, and ALT \< 2x (ULN); alkaline phosphatase and =\< 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). Subjects with Gilbert's syndrome are allowed to participate in the study.
  • Average or QTcF \< 450msec; or QTc \< 480msec in subjects with right bundle branch block.

Exclusion criteria

Exclusion Criteria:

  • A medical history of the following:

    • Clinical or angiographic cardiovascular disease, including history or current evidence of coronary heart disease, heart failure, cerebrovascular disease (including stroke and [mini-stroke]), peripheral vascular disease. Subjects pending diagnostic procedures for any of those conditions at the time of screening will not be eligible for participation.
    • Homozygous familial hypercholesterolemia or family history of familial hypercholesterolemia (Part B only). Note: Subjects with heterozygous familial hypercholesterolemia on 80mg atorvastatin who are tolerating this drug well and fulfill the other eligibility criteria may participate in Part A only.
    • History of recurrent or unexplained muscle aches (e.g., fibromyalgia), myopathy or myositis, whether or not it is related to treatment with statins or other lipid modifying drugs.
    • Renal impairment as defined by a calculated \< 60 mL/min
    • History of diabetes mellitus, or history of post-prandial and/or random blood glucose > 200 mg/dl or fasting glucose > 125 mg/dL or currently taking diabetes medications to manage fasting glucose levels (e.g., thiazolidinediones, sulfonylureas, insulin, metformin).
    • History of pancreatitis within 10 years of screening.
    • Any concurrent serious illness (e.g., severe , sleep apnea, history of other than skin cancer within 5 years of initial diagnosis or with evidence of recurrence) that may interfere with a subject from completing the study.
    • Current or chronic history of liver disease, or known hepatic or biliary abnormalities.
    • Active peptic ulcer disease and/or history of peptic ulcer disease or gastrointestinal bleeding within 12 months prior to screening.
    • History of kidney stones within 10 years of screening.
    • History of uncorrected thyroid dysfunction or an abnormal thyroid function test assessed by thyroid stimulating hormone (TSH) at Screening. (NOTE: subjects with hypothyroidism on a stable dose of thyroid replacement therapy for at least 3 months prior to screening and who have a screening TSH within the normal range may participate.)
    • Symptomatic cholelithiasis or obstructive or inflammatory gallbladder disease within 3 months prior to screening.
    • Gastrointestinal disease that could affect fat or bile acid absorption, or the pharmacokinetics or pharmacodynamics of the study drugs, including inflammatory bowel disease, chronic diarrhea, Crohn's disease or malabsorption syndromes within the past year.
    • Gastrointestinal surgery that may affect the pharmacokinetics or pharmacodynamics of the study drugs.

Note: Subjects may be enrolled in the study if they have had a cholecystectomy three or more months before the time of screening and are stable and asymptomatic.

  • Subjects taking ezetimibe monotherapy, fibrates, bile acid binding resins, nicotinic acid or fat absorption inhibitors are not eligible for Parts A and B.
  • For females a \< 11.5g/dL, and for males a hemoglobin \< 12.5g/dL.
  • Current inadequately controlled hypertension (blood pressure >= 160mmHg systolic or >= 100mmHg diastolic at screening). If blood pressure medication is changed as a result of screening, blood pressure will be re-measured after 6 weeks and must again meet these criteria.
  • Significant (ECG) abnormalities, defined as follows:

Heart Rate \< 50 and >100bpm PR Interval \<120 and > 220ms QRS duration \< 70 and >120ms (Bazett) > 450ms Or, has rhythm abnormalities identified during 24-hour screening Holter assessment. Subjects with left bundle branch block are excluded from the study. Subjects with partial right bundle branch block may be considered for inclusion following consultation with the GlaxoSmithKline (GSK) Medical Monitor. Subjects with Wolf-Parkinson-White (WPW) syndrome are excluded from the study.

  • Creatinine phosphokinase (CPK) >= 2x at screening.
  • A positive pre-study surface antigen or positive antibody result within 3 months of screening.
  • A positive test for antibody.
  • The subject has a positive pre-study drug-of-abuse screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
  • History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >14 drinks/week for men or >7 drinks/week for women. One drink is equivalent to (12 g alcohol) = 5 ounces (150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of 80 proof distilled spirits.
  • Subjects will be excluded if they require treatment with systemic .
  • Treatment with an drug within 30 days or 5 half-lives (whichever is longer) prior to dosing.
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • History of sensitivity or untoward reaction to the study medications (GSK1292263, atorvastatin or ezetimibe), or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
  • History of intolerance to statins.
  • Any change in concomitant medication (including multivitamins, herbal remedies, dietary supplements, and over-the-counter medication) within six weeks prior to screening that is not approved by GSK.
  • On a diet that may affect study outcomes, or any change in diet, exercise habits or smoking status within six weeks prior to screening or planned change during study (e.g., new exercise program) other than that in the dietary instructions in the Study Procedures Manual.
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • Where participation in study would result in donation of blood in excess of approximately 500mL within a 56 day period.
  • Subject is mentally or legally incapacitated.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Pregnant females as determined by positive urine hCG test at screening or prior to dosing.
  • Lactating females.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • Consumption of red wine, Seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
  • Unwilling to abstain from caffeine-or xanthine-containing products from Day -2 until Day 15.
  • Subject is either an immediate family member of a participating investigator, study coordinator, employee of an investigator; or is a member of the staff conducting the study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
287 participants (actual)

Study arms

  • Other
    Part A Run-in

    Subjects on stable 40mg atorvastatin \> 4 weeks may raise their dose to 80mg for 2 weeks in order to qualify for Part A.

    Drug: 80mg atorvastatin

  • Experimental
    Part A Co-Dosing 800mg GSK1292263

    Dosing for 14 days

    Drug: 800mg GSK1292263

  • Other
    Part B Washout

    Washout for 4 weeks

    Other: Washout

  • Active comparator
    Part B Run-in 10mg atorvastatin

    Dosing for 4 weeks

    Drug: 10mg atorvastatin

  • Active comparator
    Part B Run-in 80mg atorvastatin

    Dosing for 4 weeks

    Drug: 80mg atorvastatin

  • Experimental
    Part B Co-Dosing 10mg atorvastatin + 100mg GSK1292263

    Dosing for 14 days

    Drug: 10mg atorvastatin

  • Experimental
    Part B Co-Dosing 10mg atorvastatin + 300mg GSK1292263

    Dosing for 14 days

    Drug: 300mg GSK1292263

  • Experimental
    Part B Co-Dosing 10mg atorvastatin + 800mg GSK1292263

    Dosing for 14 days

    Drug: 10mg atorvastatin · Drug: 800mg GSK1292263

  • Experimental
    Part B Co-Dosing 10mg atorvastatin + 10mg ezetimibe

    Dosing for 14 days

    Drug: 10mg atorvastatin · Drug: 10mg ezetimibe

  • Experimental
    Part B Dosing 100mg GSK1292263

    Dosing for 14 days

    Drug: 100mg GSK1292263

  • Experimental
    Part B Dosing 300mg GSK1292263

    Dosing for 14 days

    Drug: 300mg GSK1292263

  • Experimental
    Part B Dosing 800mg GSK1292263

    Dosing for 14 days

    Drug: 800mg GSK1292263

  • Experimental
    Part B Dosing Placebo GSK1292263

    Dosing for 14 days

    Drug: GSK1292263 Placebo

  • Experimental
    Part B Co-Dosing 80mg atorvastatin + 800mg GSK1292263

    Dosing for 14 days

    Drug: 80mg atorvastatin

  • Experimental
    Part B Co-dosing 80mg atorvastatin + Placebo (GSK1292263)

    Dosing for 14 days

    Drug: GSK1292263 Placebo

  • Experimental
    Part B Co-Dosing 10mg atorvastatin + Placebo (GSK1292263)

    Dosing for 14 days

    Drug: 10mg atorvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)- Part A

    An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, or is an important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or a drug-induced liver injury.

    Time frame: Up to Day 26

  2. Number of Participants With Any AEs and SAEs- Part B (Washout)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, or is an important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or a drug-induced liver injury.

    Time frame: Up to Day 28

  3. Number of Participants With Any AEs and SAEs- Part B (Run-in)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, or is an important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or a drug-induced liver injury.

    Time frame: Up to Day 28

  4. Number of Participants With Any AEs and SAEs- Part B (Pooled Treatment Arm)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, or is an important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or a drug-induced liver injury.

    Time frame: Up to Day 26

  5. Number of Participants With Abnormal- Clinically Significant Electrocardiogram (ECG) Findings- Part A

    Single ECGs were taken after admission on Day -1 and at Follow-up (up to Day 26). On Days 1, 7, and 14 single ECGS were taken pre-breakfast (fasting) and at 1, 3, 6, 8, 14 and 24 hours post-dose. ECGs were taken in supine position. Additional ECGs were taken at the discretion of the investigator as needed based on symptoms or ECG findings. No value found to be abnormal clinically significant in Part A of the study.

    Time frame: Up to Day 26

  6. Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Washout)

    ECGs were taken at Screening, and on Day1 and Day 28. Single assessments were made. ECGs were taken in supine position. Additional ECGs were taken at the discretion of the investigator as needed based on symptoms or ECG findings.

    Time frame: Up to Day 28

  7. Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Run-in)

    ECGs were taken on Day 28. Single assessments were made. ECGs were taken in supine position. Additional ECGs were taken at the discretion of the investigator as needed based on symptoms or ECG findings. No data found to be abnormal clinically significant in run-in phase.

    Time frame: Day 28

  8. Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Pooled Treatment Arm)

    Single ECGs were taken after admission on Day -2, and pre-breakfast on Days -1, 4, 10, and at Follow-up. On Days 1, 7, and 14 single ECGS were taken pre-breakfast (fasting) and at 1, 3, 6, 8, 14 and 24 hours post-dose. ECGs were taken in supine position. Additional ECGs were taken at the discretion of the investigator as needed based on symptoms or ECG findings. The data was found to be abnormal clinically significant in treatment phase.

    Time frame: Up to Day 26

  9. Number of Participants With Vital Signs of Potential Clinical Importance (PCI)- Part A

    Assessment of vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate was performed after admission on Day -1 and at Follow-up. On Days 1, 7 and 14, they were taken at pre-dose, 1, 3, 6, 8, 14 and 24 hours after the morning dose. At each time point, assessment was performed after resting in a supine or semi-supine position for at least 10 minutes. Data for only those parameters are presented for which findings are of PCI either high or low.

    Time frame: Up to Day 26

  10. Number of Participants With Vital Signs of PCI- Part B (Washout)

    Assessment of vital signs including SBP, DBP heart rate was performed at Screening, on Days 1, 14 and 28 in the morning. At each time point, assessment was performed after resting in a supine or semi-supine position for at least 10 minutes. Data for only those parameters are presented for which findings are of PCI either high or low.

    Time frame: Up to day 28

  11. Number of Participants With Vital Signs of Potential Clinical Importance- Part B (Run-in)

    Assessment of vital signs including SBP, DBP and heart rate was performed on Days 1, 14 and 28 in the morning. At each time point, assessment was performed after resting in a supine or semi-supine position for at least 10 minutes. Data for only those parameters are presented for which findings are of PCI either high or low.

    Time frame: Up to day 28

  12. Number of Participants With Vital Signs of Potential Clinical Importance- Part B (Pooled Treatment Arm)

    Assessment of vital signs including SBP, DBP and heart rate was performed after admission on Day-2, and pre-breakfast on Days -1, 4, and 10 in a fasting state early in the morning (prior to dosing), and at Follow-up. On Days 1, 7 and 14, they were also be taken at 1, 3, 6, 9, 12 and 24 hours after the morning dose. At each time point, assessment was performed after resting in a supine or semi-supine position for at least 10 minutes. Data for only those parameters are presented for which findings are of PCI either high or low.

    Time frame: Up to Day 26

  13. Number of Participants With Abnormal Hematology Value of PCI- Part A

    Blood samples were collected fasting on Day -1, and prior to breakfast (early in the morning, fasting) on Days 2, 4, 7, 11 and on Day 15 prior to checkout (24 hours post last-dose), and at Follow-up. When this resulted in multiple samples at the same time point, only one sample was collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Data for only those parameters (Hematocrit, Hemoglobin and Total neutrophils) are presented for which findings are of PCI either high or low.

    Time frame: Up to Day 26

  14. Number of Participants With Abnormal Hematology Value of PCI- Part B (Washout)

    Blood samples were collected at screening, and on Days 1 (first day of washout), 14 and 28 prior to breakfast (early in the morning, fasting). Data for only those parameters (White blood cells \[WBC\], Total neutrophils, Hematocrit and Lymphocytes) are presented for which findings are of PCI either high or low.

    Time frame: Up to Day 28

  15. Number of Participants With Abnormal Hematology Value of PCI- Part B (Run-in)

    Blood samples were collected on Day 14 and 28 prior to breakfast (early in the morning, fasting). Data for only those parameters (Lymphocytes) are presented for which findings are of PCI either high or low.

    Time frame: Days 14 and 28

  16. Number of Participants With Abnormal Hematology Value of PCI- Part B (Pooled Treatment Arm)

    Blood samples were collected fasting on Day -2, and prior to breakfast (early in the morning, fasting) on Days 2 (pre-dose), 4, 7, 10, 13 and on Day 15 prior to checkout (24hrs post-dose), and at Follow-up. When this resulted in multiple samples at the same time point, only one sample was collected (example, when 24hrs post dose = pre-dose (time 0) for the next dose). Data for only those parameters (Platelet count, Total neutrophils and Lymphocytes) are presented for which findings are of PCI either high or low.

    Time frame: Up to Day 26

  17. Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part A

    Samples were collected fasting on Day -1, and prior to breakfast (early in the morning, fasting) on Days 2, 4, 7, 11 and on Day 15 prior to checkout (24 hours post last-dose), and at Follow-up. When this resulted in multiple samples at the same time point, only one sample was collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). No parameter was found to have any value of PCI.

    Time frame: Up to Day 26

  18. Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (Washout)

    Samples were collected at screening, and on Days1 (first day of washout), 14 and 28 prior to breakfast (early in the morning, fasting). Data for only those parameters (Inorganic phosphorus, Sodium, Alanine aminotransferase \[ALT\], Potassium, Creatinine, Calcium, magnesium, Glucose, Total Bilirubin, Carbon dioxide/bicarbonate \[CO2/HCO3\] and Aspartate aminotransferase \[AST\]) are presented for which findings are of PCI either high or low.

    Time frame: Up to Day 28

  19. Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (run-in)

    Samples were collected on Day 14 and 28 prior to breakfast (early in the morning, fasting). Data for only those parameters (Glucose, Magnesium, ALT, AST, Calcium, Inorganic phosphorus and Total bilirubin) are presented for which findings are of PCI either high or low.

    Time frame: Days 14 and 28

  20. Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (Pooled Treatment Arm)

    Samples were collected fasting on Day -2, and prior to breakfast (early in the morning, fasting) on Days 2 (pre-dose), 4, 7, 10, 13 and on Day 15 prior to checkout (24 hours post-dose), and at Follow-up. When this resulted in multiple samples at the same time point, only one sample was collected (example, when 24 hours post dose = pre-dose (time 0) for the next dose). Data for only those parameters (Glucose, Total bilirubin, Albumin, Magnesium, CO2/HCO3, Calcium, ALT, AST, Inorganic phosphorus, Potassium and Sodium) are presented for which findings are of PCI either high or low.

    Time frame: Up to Day 26

  21. Maximum Observed Concentration (Cmax) of GSK1292263- Part A

    Serial blood samples for the determination of the PK for GSK1292263 on Days 1 and 14 were collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (no 48 hour sample on Day 1).

    Time frame: On Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

  22. Cmax of GSK1292263- Part B (Pooled Treatment Arm)

    For co-dosing arms, serial blood samples for the determination of the PK of GSK1292263 were taken on Days 1 and 14. For monotherapy arms, serial blood samples for the determination of the PK of GSK1292263 were collected on Days 1 and 14. Blood samples for PK were collected on Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hours PK sample was collected on Day 16).

    Time frame: On Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. On Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

  23. Time of Occurrence of Cmax (Tmax) and Terminal Phase Half-life (t1/2) GSK1292263- Part A

    Serial blood samples for the determination of the PK for GSK1292263, on Days 1 and 14 were collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (no 48 hour sample on Day 1).

    Time frame: On Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

  24. Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) of GSK1292263- Part A

    Serial blood samples for the determination of the PK for GSK1292263 on Days 1 were collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (no 48h sample on Day 1).

    Time frame: On Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

  25. Tmax and t1/2 of GSK1292263- Part B (Pooled Treatment Arm)

    For co-dosing arms, serial blood samples for the determination of the PK of GSK1292263 were taken on Days 1 and 14. For monotherapy arms, serial blood samples for the determination of the PK of GSK1292263 were collected on Days 1 and 14. Blood samples for PK were collected on Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hours PK sample was collected on Day 16).

    Time frame: On Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. On Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

  26. Tlag of GSK1292263- Part B (Pooled Treatment Arm)

    Blood samples for PK were collected on Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose.

    Time frame: On Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose.

  27. Area Under the Concentration-time Curve From Time Zero (Pre-dose) to 24 Hours [AUC(0-24)] of GSK1292263- Part A

    Serial blood samples for the determination of the PK for GSK1292263, on Days 1 and 14 were collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (no 48 hour sample on Day 1).

    Time frame: On Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

  28. AUC(0-24) of GSK1292263- Part B (Pooled Treatment Arm)

    For co-dosing arms, serial blood samples for the determination of the PK of GSK1292263 were taken on Days 1 and 14. For monotherapy arms, serial blood samples for the determination of the PK of GSK1292263 were collected on Days 1 and 14. Blood samples for PK were collected on Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hours PK sample was collected on Day 16).

    Time frame: On Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. On Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

  29. Trough Concentration of GSK1292263

    Trough samples for GSK1292263 PK (all treatment arms) were planned to be collected early in the morning on Days 13, 14, 15 and 16 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48h PK sample was collected on Day 16). (pre-dose for Days 13 and 14; trough Day 15 = 24h post last dose; trough Day 16 = 48h post last dose).

    Time frame: On Days 13, 14, 15 and 16 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

  30. Cmax of Atorvastatin- Part A

    Serial blood samples for the determination of the PK for atorvastatin on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).

    Time frame: On Day -1 at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose. on Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose.

  31. Cmax of Atorvastatin- Part B (Pooled Treatment Arm)

    For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).

    Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

  32. Tmax of Atorvastatin- Part A

    Serial blood samples for the determination of the PK for atorvastatin on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).

    Time frame: On Day -1 at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose. on Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose.

  33. Tmax of Atorvastatin- Part B (Pooled Treatment Arm)

    For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).

    Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

  34. AUC (0-24) of Atorvastatin- Part A

    For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).

    Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

  35. AUC (0-24) of Atorvastatin- Part B (Pooled Treatment Arm)

    For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).

    Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

  36. Trough Concentration of Atorvastatin

    For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were planned to be collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were planned to be collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were planned to be collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was planned to be collected on Day 16).

    Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

  37. Percent Change From Baseline for Lipid Metabolism: Apolipoprotein A1 and Apolipoprotein B100 at Day 14

    Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was the closest scheduled value prior to dosing. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.

    Time frame: Baseline and Day 14

  38. Percent Change From Baseline in Lipid Metabolism: Apolipoprotein E at Day 14 (24 Hours)

    Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was the closest scheduled value prior to dosing. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.

    Time frame: Baseline and Day 14

  39. Percent Change From Baseline in Lipid Metabolism: High Density Lipids Cholesterol (HDLc), Low Density Lipids Cholesterol (LDLc), Tryglycerides, Non-HDLc and Total Cholesterol at Day 14 (24 Hours)

    Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was the closest scheduled value prior to dosing. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.

    Time frame: Baseline and Day 14

  40. Percent Change From Baseline in Lipid Metabolism: LDL/HDL Ratio at Day 14 (24 Hours)

    Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was the closest scheduled value prior to dosing. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.

    Time frame: Baseline and Day 14

  41. Weighted Mean Area Under Concentration Curve From 0 to 24 Hours (AUC [0-24]) Change From Baseline for Triglycerides at Day 14

    Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was Day -1 value. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.

    Time frame: Baseline and Day 14

Secondary outcomes

  1. Cmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A

    Serial blood samples for the determination of the PK for atorvastatin metabolites on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin metabolites on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).

    Time frame: On Day -1 at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose. on Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose.

  2. Cmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)

    For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin metabolites were collected on Day -1 and for atorvastatin metabolites on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).

    Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

  3. Tmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A

    Serial blood samples for the determination of the PK for atorvastatin metabolites on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin metabolites on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).

    Time frame: On Day -1 at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose. on Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose.

  4. Tmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)

    For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin metabolites were collected on Day -1 and for atorvastatin metabolites on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).

    Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose and on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

  5. AUC (0-24) of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A

    Serial blood samples for the determination of the PK for atorvastatin metabolites on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin metabolites on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).

    Time frame: On Day -1 at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose. on Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose.

  6. AUC (0-24) of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)

    For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin metabolites were collected on Day -1 and for atorvastatin metabolites on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).

    Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

  7. Trough Concentration of Atorvastatin Metabolite (2-Hydroxyatorvastatin)

    For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin metabolites were supposed to collected on Day -1 and for atorvastatin metabolites on Days 1 and 14. Blood samples for PK were supposed to collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were supposed to collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16). However no data was collected.

    Time frame: On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

07

Results

Posted Nov 8, 2017

Participant flow

The study was conducted at 21 centers in the United States during the period 14 September 2010 to 29 June 2011. There were 6 total participants in Part A, then Part B started with total of 281 participants which flowed through the rest of the phases of the trial. Part B had washout phase and run-In phase followed by treatment phase.

Part A
Participant flow — Part A
MilestonePart APart B WashoutPart B Run-inPart B Pooled Treatment Arm
Started6000
Completed6000
Not completed0000
Part B Washout
Participant flow — Part B Washout
MilestonePart APart B WashoutPart B Run-inPart B Pooled Treatment Arm
Started028100
Completed013600
Not completed014500
Withdrew: Adverse event0100
Withdrew: Lost to follow-up0200
Withdrew: Physician decision01400
Withdrew: Withdrawal by subject01400
Withdrew: Reached defined stopping criteria0200
Withdrew: Did not meet continuation criteria011200
Part B Run-in
Participant flow — Part B Run-in
MilestonePart APart B WashoutPart B Run-inPart B Pooled Treatment Arm
Started00890
Completed00830
Not completed0060
Withdrew: Adverse event0010
Withdrew: Protocol violation0020
Withdrew: Withdrawal by subject0030
Part B Pooled Treatment Arm
Participant flow — Part B Pooled Treatment Arm
MilestonePart APart B WashoutPart B Run-inPart B Pooled Treatment Arm
Started000130
Completed000127
Not completed0003
Withdrew: Adverse event0002
Withdrew: Protocol violation0001

Outcome measures

PrimaryNumber of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)- Part A

An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, or is an important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or a drug-induced liver injury.

Time frame:
Up to Day 26
Reported as:
Count of participants · Participants
Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)- Part A
Participants80 mg Atorvastatin + 800 mg GSK1292263800 mg GSK1292263
Any AE02
Any SAE00
PrimaryNumber of Participants With Any AEs and SAEs- Part B (Washout)

An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, or is an important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or a drug-induced liver injury.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Any AEs and SAEs- Part B (Washout)
ParticipantsPre-treatmentWashout
Any AE1437
Any SAE00
PrimaryNumber of Participants With Any AEs and SAEs- Part B (Run-in)

An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, or is an important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or a drug-induced liver injury.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Any AEs and SAEs- Part B (Run-in)
ParticipantsAtorvastatin 10 mgAtorvastatin 80 mg
Any AE198
Any SAE00
PrimaryNumber of Participants With Any AEs and SAEs- Part B (Pooled Treatment Arm)

An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, or is an important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or a drug-induced liver injury.

Time frame:
Up to Day 26
Reported as:
Count of participants · Participants
Number of Participants With Any AEs and SAEs- Part B (Pooled Treatment Arm)
ParticipantsAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 10 mg + PlaceboAtorvastatin 10 mg + Ezetimibe 10 mgAtorvastatin 80 mg + GSK1292263 800 mgAtorvastatin 80 mg + PlaceboGSK1292263 100 mgGSK1292263 300 mgGSK1292263 800 mgPlacebo
Any AE62334645784
Any SAE00000000000
PrimaryNumber of Participants With Abnormal- Clinically Significant Electrocardiogram (ECG) Findings- Part A

Single ECGs were taken after admission on Day -1 and at Follow-up (up to Day 26). On Days 1, 7, and 14 single ECGS were taken pre-breakfast (fasting) and at 1, 3, 6, 8, 14 and 24 hours post-dose. ECGs were taken in supine position. Additional ECGs were taken at the discretion of the investigator as needed based on symptoms or ECG findings. No value found to be abnormal clinically significant in Part A of the study.

Time frame:
Up to Day 26
Reported as:
Count of participants · Participants
Number of Participants With Abnormal- Clinically Significant Electrocardiogram (ECG) Findings- Part A
ParticipantsAtorvastatin 80 mg + GSK1292263 800 mgGSK1292263 800 mg
Number of Participants With Abnormal- Clinically Significant Electrocardiogram (ECG) Findings- Part A00
PrimaryNumber of Participants With Abnormal Clinically Significant ECG Findings- Part B (Washout)

ECGs were taken at Screening, and on Day1 and Day 28. Single assessments were made. ECGs were taken in supine position. Additional ECGs were taken at the discretion of the investigator as needed based on symptoms or ECG findings.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Washout)
ParticipantsWashout
Day 11
Day 281
PrimaryNumber of Participants With Abnormal Clinically Significant ECG Findings- Part B (Run-in)

ECGs were taken on Day 28. Single assessments were made. ECGs were taken in supine position. Additional ECGs were taken at the discretion of the investigator as needed based on symptoms or ECG findings. No data found to be abnormal clinically significant in run-in phase.

Time frame:
Day 28
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Run-in)
ParticipantsAtorvastatin 10 mgAtorvastatin 80 mg
Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Run-in)00
PrimaryNumber of Participants With Abnormal Clinically Significant ECG Findings- Part B (Pooled Treatment Arm)

Single ECGs were taken after admission on Day -2, and pre-breakfast on Days -1, 4, 10, and at Follow-up. On Days 1, 7, and 14 single ECGS were taken pre-breakfast (fasting) and at 1, 3, 6, 8, 14 and 24 hours post-dose. ECGs were taken in supine position. Additional ECGs were taken at the discretion of the investigator as needed based on symptoms or ECG findings. The data was found to be abnormal clinically significant in treatment phase.

Time frame:
Up to Day 26
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Pooled Treatment Arm)
ParticipantsAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 10 mg + PlaceboAtorvastatin 10 mg + Ezetimibe 10 mgAtorvastatin 80 mg + GSK1292263 800 mgAtorvastatin 80 mg + PlaceboGSK1292263 100 mgGSK1292263 300 mgGSK1292263 800 mgPlacebo
Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Pooled Treatment Arm)00000000000
PrimaryNumber of Participants With Vital Signs of Potential Clinical Importance (PCI)- Part A

Assessment of vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate was performed after admission on Day -1 and at Follow-up. On Days 1, 7 and 14, they were taken at pre-dose, 1, 3, 6, 8, 14 and 24 hours after the morning dose. At each time point, assessment was performed after resting in a supine or semi-supine position for at least 10 minutes. Data for only those parameters are presented for which findings are of PCI either high or low.

Time frame:
Up to Day 26
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs of Potential Clinical Importance (PCI)- Part A
ParticipantsAtorvastatin 80 mg + GSK1292263 800 mgGSK1292263 800 mg
DBP, high01
DBP, low00
PrimaryNumber of Participants With Vital Signs of PCI- Part B (Washout)

Assessment of vital signs including SBP, DBP heart rate was performed at Screening, on Days 1, 14 and 28 in the morning. At each time point, assessment was performed after resting in a supine or semi-supine position for at least 10 minutes. Data for only those parameters are presented for which findings are of PCI either high or low.

Time frame:
Up to day 28
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs of PCI- Part B (Washout)
ParticipantsWashout
SBP, high4
Heart rate, high1
PrimaryNumber of Participants With Vital Signs of Potential Clinical Importance- Part B (Run-in)

Assessment of vital signs including SBP, DBP and heart rate was performed on Days 1, 14 and 28 in the morning. At each time point, assessment was performed after resting in a supine or semi-supine position for at least 10 minutes. Data for only those parameters are presented for which findings are of PCI either high or low.

Time frame:
Up to day 28
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs of Potential Clinical Importance- Part B (Run-in)
ParticipantsAtorvastatin 10 mgAtorvastatin 80 mg
SBP, high10
SBP, low00
PrimaryNumber of Participants With Vital Signs of Potential Clinical Importance- Part B (Pooled Treatment Arm)

Assessment of vital signs including SBP, DBP and heart rate was performed after admission on Day-2, and pre-breakfast on Days -1, 4, and 10 in a fasting state early in the morning (prior to dosing), and at Follow-up. On Days 1, 7 and 14, they were also be taken at 1, 3, 6, 9, 12 and 24 hours after the morning dose. At each time point, assessment was performed after resting in a supine or semi-supine position for at least 10 minutes. Data for only those parameters are presented for which findings are of PCI either high or low.

Time frame:
Up to Day 26
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs of Potential Clinical Importance- Part B (Pooled Treatment Arm)
ParticipantsAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 10 mg + PlaceboAtorvastatin 10 mg + Ezetimibe 10 mgAtorvastatin 80 mg + GSK1292263 800 mgAtorvastatin 80 mg + PlaceboGSK1292263 100 mgGSK1292263 300 mgGSK1292263 800 mgPlacebo
SBP, high00132121200
DBP, high00010101000
DBP, low00001101000
Heart rate, high00010000000
PrimaryNumber of Participants With Abnormal Hematology Value of PCI- Part A

Blood samples were collected fasting on Day -1, and prior to breakfast (early in the morning, fasting) on Days 2, 4, 7, 11 and on Day 15 prior to checkout (24 hours post last-dose), and at Follow-up. When this resulted in multiple samples at the same time point, only one sample was collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Data for only those parameters (Hematocrit, Hemoglobin and Total neutrophils) are presented for which findings are of PCI either high or low.

Time frame:
Up to Day 26
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Hematology Value of PCI- Part A
ParticipantsAtorvastatin 80 mg + GSK1292263 800 mgGSK1292263 800 mg
Hematocrit, high21
Hemoglobin, high20
Total neutrophil, low10
PrimaryNumber of Participants With Abnormal Hematology Value of PCI- Part B (Washout)

Blood samples were collected at screening, and on Days 1 (first day of washout), 14 and 28 prior to breakfast (early in the morning, fasting). Data for only those parameters (White blood cells \[WBC\], Total neutrophils, Hematocrit and Lymphocytes) are presented for which findings are of PCI either high or low.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Hematology Value of PCI- Part B (Washout)
ParticipantsWashout
WBC, high1
WBC, low1
Total neutrophil, low1
Hematocrit, high2
Lymphocytes, low2
PrimaryNumber of Participants With Abnormal Hematology Value of PCI- Part B (Run-in)

Blood samples were collected on Day 14 and 28 prior to breakfast (early in the morning, fasting). Data for only those parameters (Lymphocytes) are presented for which findings are of PCI either high or low.

Time frame:
Days 14 and 28
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Hematology Value of PCI- Part B (Run-in)
ParticipantsAtorvastatin 10 mgAtorvastatin 80 mg
Lymphocytes, low01
Lymphocytes, high00
PrimaryNumber of Participants With Abnormal Hematology Value of PCI- Part B (Pooled Treatment Arm)

Blood samples were collected fasting on Day -2, and prior to breakfast (early in the morning, fasting) on Days 2 (pre-dose), 4, 7, 10, 13 and on Day 15 prior to checkout (24hrs post-dose), and at Follow-up. When this resulted in multiple samples at the same time point, only one sample was collected (example, when 24hrs post dose = pre-dose (time 0) for the next dose). Data for only those parameters (Platelet count, Total neutrophils and Lymphocytes) are presented for which findings are of PCI either high or low.

Time frame:
Up to Day 26
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Hematology Value of PCI- Part B (Pooled Treatment Arm)
ParticipantsAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 10 mg + PlaceboAtorvastatin 10 mg + Ezetimibe 10 mgAtorvastatin 80 mg + GSK1292263 800 mgAtorvastatin 80 mg + PlaceboGSK1292263 100 mgGSK1292263 300 mgGSK1292263 800 mgPlacebo
Platelet count, low01000000000
Total neutrophils, low01100000001
Lymphocytes, low00000011000
PrimaryNumber of Participants With Abnormal Clinical Chemistry Value of PCI- Part A

Samples were collected fasting on Day -1, and prior to breakfast (early in the morning, fasting) on Days 2, 4, 7, 11 and on Day 15 prior to checkout (24 hours post last-dose), and at Follow-up. When this resulted in multiple samples at the same time point, only one sample was collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). No parameter was found to have any value of PCI.

Time frame:
Up to Day 26
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part A
ParticipantsAtorvastatin 80 mg + GSK1292263 800 mgGSK1292263 800 mg
Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part A00
PrimaryNumber of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (Washout)

Samples were collected at screening, and on Days1 (first day of washout), 14 and 28 prior to breakfast (early in the morning, fasting). Data for only those parameters (Inorganic phosphorus, Sodium, Alanine aminotransferase \[ALT\], Potassium, Creatinine, Calcium, magnesium, Glucose, Total Bilirubin, Carbon dioxide/bicarbonate \[CO2/HCO3\] and Aspartate aminotransferase \[AST\]) are presented for which findings are of PCI either high or low.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (Washout)
ParticipantsWashout
Inorganic phosphorus, high3
Inorganic phosphorus, low2
Sodium, high1
Sodium, low1
ALT, high3
Potassium, high3
Potassium, low1
Creatinine, high1
Calcium, high2
Magnesium, high32
Glucose, high4
Glucose, low1
Total bilirubin, high6
CO2/bicarbonate, low1
AST, high1
PrimaryNumber of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (run-in)

Samples were collected on Day 14 and 28 prior to breakfast (early in the morning, fasting). Data for only those parameters (Glucose, Magnesium, ALT, AST, Calcium, Inorganic phosphorus and Total bilirubin) are presented for which findings are of PCI either high or low.

Time frame:
Days 14 and 28
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (run-in)
ParticipantsAtorvastatin 10 mgAtorvastatin 80 mg
Glucose, high10
Magnesium, high55
ALT, high10
AST, high10
Calcium, high01
Inorganic phosphorus, low01
Total bilirubin, high01
PrimaryNumber of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (Pooled Treatment Arm)

Samples were collected fasting on Day -2, and prior to breakfast (early in the morning, fasting) on Days 2 (pre-dose), 4, 7, 10, 13 and on Day 15 prior to checkout (24 hours post-dose), and at Follow-up. When this resulted in multiple samples at the same time point, only one sample was collected (example, when 24 hours post dose = pre-dose (time 0) for the next dose). Data for only those parameters (Glucose, Total bilirubin, Albumin, Magnesium, CO2/HCO3, Calcium, ALT, AST, Inorganic phosphorus, Potassium and Sodium) are presented for which findings are of PCI either high or low.

Time frame:
Up to Day 26
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (Pooled Treatment Arm)
ParticipantsAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 10 mg + PlaceboAtorvastatin 10 mg + Ezetimibe 10 mgAtorvastatin 80 mg + GSK1292263 800 mgAtorvastatin 80 mg + PlaceboGSK1292263 100 mgGSK1292263 300 mgGSK1292263 800 mgPlacebo
Glucose, high20001001000
Glucose, low00000000100
Total bilirubin, high20011100001
Albumin, low01010000010
Magnesium, high01211232322
CO2/HCO3, high00000000001
CO2/HCO3, low01000000000
Calcium, high00000010000
Calcium, low01001000010
ALT, high00100000000
AST, high00100000000
Inorganic phosphorus, high00002000000
Potassium, low00000000100
Sodium, high00000000010
PrimaryMaximum Observed Concentration (Cmax) of GSK1292263- Part A

Serial blood samples for the determination of the PK for GSK1292263 on Days 1 and 14 were collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (no 48 hour sample on Day 1).

Time frame:
On Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Reported as:
Geometric mean · nanograms per milliliter
Maximum Observed Concentration (Cmax) of GSK1292263- Part A
nanograms per milliliterAtorvastatin 80 mg + GSK1292263 800 mgGSK1292263 800 mg
Day 1976.335 ± 16.6353986.811 ± 46.4825
Day 141118.344 ± 20.6141948.764 ± 6.5356
PrimaryCmax of GSK1292263- Part B (Pooled Treatment Arm)

For co-dosing arms, serial blood samples for the determination of the PK of GSK1292263 were taken on Days 1 and 14. For monotherapy arms, serial blood samples for the determination of the PK of GSK1292263 were collected on Days 1 and 14. Blood samples for PK were collected on Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hours PK sample was collected on Day 16).

Time frame:
On Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. On Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Reported as:
Geometric mean · nanograms per milliliter
Cmax of GSK1292263- Part B (Pooled Treatment Arm)
nanograms per milliliterAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 80 mg + GSK1292263 800 mgGSK1292263 100 mgGSK1292263 300 mgGSK1292263 800 mg
Day 1281.321 ± 35.9671475.297 ± 36.5131808.278 ± 20.0646790.315 ± 32.5080263.279 ± 43.0140478.676 ± 21.2079787.922 ± 36.7864
Day 14361.595 ± 25.9981639.687 ± 33.6608886.418 ± 31.3931848.082 ± 25.1892364.936 ± 39.1918590.949 ± 20.7601782.914 ± 81.2992
PrimaryTime of Occurrence of Cmax (Tmax) and Terminal Phase Half-life (t1/2) GSK1292263- Part A

Serial blood samples for the determination of the PK for GSK1292263, on Days 1 and 14 were collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (no 48 hour sample on Day 1).

Time frame:
On Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Reported as:
Median · hours
Time of Occurrence of Cmax (Tmax) and Terminal Phase Half-life (t1/2) GSK1292263- Part A
hoursAtorvastatin 80 mg + GSK1292263 800 mgGSK1292263 800 mg
tmax, Day 16.000 (4.00 to 8.00)5.000 (4.00 to 6.00)
tmax, Day 143.000 (3.00 to 4.00)5.067 (4.00 to 6.13)
t1/2, Day 111.185 (8.81 to 11.61)16.164 (16.164 to 16.164)
t1/2, Day 1420.629 (13.76 to 28.80)19.395 (16.54 to 22.25)
PrimaryLag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) of GSK1292263- Part A

Serial blood samples for the determination of the PK for GSK1292263 on Days 1 were collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (no 48h sample on Day 1).

Time frame:
On Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Reported as:
Median · hours
Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) of GSK1292263- Part A
hoursAtorvastatin 80 mg + GSK1292263 800 mgGSK1292263 800 mg
Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) of GSK1292263- Part A0.250 (0.00 to 0.50)0.000 (0.00 to 0.00)
PrimaryTmax and t1/2 of GSK1292263- Part B (Pooled Treatment Arm)

For co-dosing arms, serial blood samples for the determination of the PK of GSK1292263 were taken on Days 1 and 14. For monotherapy arms, serial blood samples for the determination of the PK of GSK1292263 were collected on Days 1 and 14. Blood samples for PK were collected on Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hours PK sample was collected on Day 16).

Time frame:
On Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. On Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Reported as:
Median · hours
Tmax and t1/2 of GSK1292263- Part B (Pooled Treatment Arm)
hoursAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 80 mg + GSK1292263 800 mgGSK1292263 100 mgGSK1292263 300 mgGSK1292263 800 mg
tmax, Day 13.983 (3.00 to 6.00)5.008 (3.98 to 8.00)4.000 (4.00 to 8.33)4.000 (3.98 to 8.08)4.000 (1.50 to 8.00)4.000 (2.00 to 8.00)3.475 (1.98 to 7.97)
tmax, Day 145.000 (0.83 to 8.00)4.000 (2.08 to 4.02)4.000 (1.50 to 4.05)4.000 (1.50 to 4.00)4.000 (3.98 to 6.00)3.983 (1.98 to 6.00)4.000 (0.43 to 5.98)
t1/2, Day 112.630 (12.63 to 12.63)10.270 (6.07 to 10.55)10.416 (9.29 to 26.11)12.372 (6.72 to 23.08)15.305 (12.25 to 21.78)14.342 (13.38 to 20.30)14.464 (14.464 to 14.464)
t1/2, Day 1426.453 (17.02 to 163.25)21.569 (15.73 to 37.15)21.846 (10.52 to 36.52)24.225 (16.86 to 34.21)23.893 (17.43 to 43.62)25.203 (10.67 to 62.63)19.478 (12.40 to 67.78)
PrimaryTlag of GSK1292263- Part B (Pooled Treatment Arm)

Blood samples for PK were collected on Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose.

Time frame:
On Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose.
Reported as:
Median · hours
Tlag of GSK1292263- Part B (Pooled Treatment Arm)
hoursAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 80 mg + GSK1292263 800 mgGSK1292263 100 mgGSK1292263 300 mgGSK1292263 800 mg
Tlag of GSK1292263- Part B (Pooled Treatment Arm)0.000 (0.00 to 0.50)0.000 (0.00 to 0.50)0.000 (0.00 to 1.03)0.000 (0.00 to 0.50)0.000 (0.00 to 1.03)0.000 (0.00 to 1.00)0.000 (0.00 to 0.50)
PrimaryArea Under the Concentration-time Curve From Time Zero (Pre-dose) to 24 Hours [AUC(0-24)] of GSK1292263- Part A

Serial blood samples for the determination of the PK for GSK1292263, on Days 1 and 14 were collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (no 48 hour sample on Day 1).

Time frame:
On Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Reported as:
Geometric mean · nanograms hour per milliliter
Area Under the Concentration-time Curve From Time Zero (Pre-dose) to 24 Hours [AUC(0-24)] of GSK1292263- Part A
nanograms hour per milliliterAtorvastatin 80 mg + GSK1292263 800 mgGSK1292263 800 mg
Day 112953.89 ± 16.97612032.21 ± NA
Day 1413206.52 ± 15.07011890.40 ± 5.730
PrimaryAUC(0-24) of GSK1292263- Part B (Pooled Treatment Arm)

For co-dosing arms, serial blood samples for the determination of the PK of GSK1292263 were taken on Days 1 and 14. For monotherapy arms, serial blood samples for the determination of the PK of GSK1292263 were collected on Days 1 and 14. Blood samples for PK were collected on Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hours PK sample was collected on Day 16).

Time frame:
On Day 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. On Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Reported as:
Geometric mean · nanograms hour per milliliter
AUC(0-24) of GSK1292263- Part B (Pooled Treatment Arm)
nanograms hour per milliliterAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 80 mg + GSK1292263 800 mgGSK1292263 100 mgGSK1292263 300 mgGSK1292263 800 mg
Day 14218.02 ± 54.2645373.78 ± 64.02110384.24 ± 15.1659812.21 ± 25.7082753.61 ± 48.5355342.77 ± 18.1088937.99 ± 21.080
Day 144968.29 ± 24.6837484.67 ± 51.77211224.58 ± 44.08710760.74 ± 22.0814061.78 ± 35.2426737.82 ± 28.0828837.31 ± 79.003
PrimaryTrough Concentration of GSK1292263

Trough samples for GSK1292263 PK (all treatment arms) were planned to be collected early in the morning on Days 13, 14, 15 and 16 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48h PK sample was collected on Day 16). (pre-dose for Days 13 and 14; trough Day 15 = 24h post last dose; trough Day 16 = 48h post last dose).

Time frame:
On Days 13, 14, 15 and 16 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

No measurements were reported for this outcome.

PrimaryCmax of Atorvastatin- Part A

Serial blood samples for the determination of the PK for atorvastatin on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).

Time frame:
On Day -1 at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose. on Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose.
Reported as:
Geometric mean · nanograms per milliliter
Cmax of Atorvastatin- Part A
nanograms per milliliterAtorvastatin 80 mg + GSK1292263 800 mg
Day -145.587 ± 130.4168
Day 125.867 ± 88.8156
Day 1438.443 ± 71.1418
PrimaryCmax of Atorvastatin- Part B (Pooled Treatment Arm)

For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).

Time frame:
On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Reported as:
Geometric mean · nanograms per milliliter
Cmax of Atorvastatin- Part B (Pooled Treatment Arm)
nanograms per milliliterAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 10 mg + PlaceboAtorvastatin 10 mg + Ezetimibe 10 mgAtorvastatin 80 mg + GSK1292263 800 mgAtorvastatin 80 mg + Placebo
Day -12.045 ± 41.39802.454 ± 34.68201.683 ± 54.13881.816 ± 54.66082.003 ± 73.291242.376 ± 113.127637.058 ± 47.5590
Day 11.292 ± 26.63452.195 ± 47.69891.926 ± 47.08991.852 ± 57.64721.872 ± 64.176231.018 ± 81.513645.781 ± 38.4790
Day 141.453 ± 14.52582.154 ± 69.08562.139 ± 74.25241.640 ± 68.67541.949 ± 56.774738.419 ± 71.205941.092 ± 73.0152
PrimaryTmax of Atorvastatin- Part A

Serial blood samples for the determination of the PK for atorvastatin on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).

Time frame:
On Day -1 at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose. on Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose.
Reported as:
Median · hours
Tmax of Atorvastatin- Part A
hoursAtorvastatin 80 mg + GSK1292263 800 mg
Day -13.000 (0.50 to 4.00)
Day 14.000 (3.00 to 6.00)
Day 142.250 (1.00 to 3.00)
PrimaryTmax of Atorvastatin- Part B (Pooled Treatment Arm)

For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).

Time frame:
On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Reported as:
Median · hours
Tmax of Atorvastatin- Part B (Pooled Treatment Arm)
hoursAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 10 mg + PlaceboAtorvastatin 10 mg + Ezetimibe 10 mgAtorvastatin 80 mg + GSK1292263 800 mgAtorvastatin 80 mg + Placebo
Day -12.500 (0.50 to 6.08)3.000 (1.50 to 6.00)3.983 (0.50 to 5.97)3.017 (0.50 to 6.08)4.000 (3.00 to 4.00)2.508 (0.50 to 6.00)1.517 (0.50 to 4.00)
Day 14.992 (3.98 to 6.00)6.000 (3.95 to 6.00)3.000 (0.50 to 8.33)3.992 (1.50 to 6.08)4.000 (2.00 to 4.00)3.492 (1.03 to 6.03)2.000 (0.50 to 4.00)
Day 144.000 (2.83 to 6.00)4.000 (3.00 to 6.00)3.500 (1.50 to 6.08)3.525 (1.50 to 6.00)2.000 (1.00 to 3.00)2.067 (0.50 to 5.93)3.000 (1.00 to 6.05)
PrimaryAUC (0-24) of Atorvastatin- Part A

For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).

Time frame:
On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Reported as:
Geometric mean · nanograms hour per milliliter
AUC (0-24) of Atorvastatin- Part A
nanograms hour per milliliterAtorvastatin 80 mg + GSK1292263 800 mg
Day -1219.27 ± 77.893
Day 1199.15 ± 73.974
Day 14187.25 ± 52.566
PrimaryAUC (0-24) of Atorvastatin- Part B (Pooled Treatment Arm)

For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).

Time frame:
On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Reported as:
Geometric mean · nanograms hour per milliliter
AUC (0-24) of Atorvastatin- Part B (Pooled Treatment Arm)
nanograms hour per milliliterAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 10 mg + PlaceboAtorvastatin 10 mg + Ezetimibe 10 mgAtorvastatin 80 mg + GSK1292263 800 mgAtorvastatin 80 mg + Placebo
Day -123.16 ± 18.11528.78 ± 26.61119.26 ± 54.76718.77 ± 51.12219.59 ± 47.952188.88 ± 70.744173.62 ± 31.333
Day 117.84 ± 35.02826.19 ± 30.56120.83 ± 50.42719.33 ± 55.62019.05 ± 48.448174.13 ± 55.829186.73 ± 35.837
Day 1415.58 ± 14.93423.77 ± 38.50120.41 ± 70.60218.60 ± 56.10220.24 ± 41.371174.93 ± 59.199188.31 ± 54.020
PrimaryTrough Concentration of Atorvastatin

For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin were planned to be collected on Day -1 and for atorvastatin on Days 1 and 14. Blood samples for PK were planned to be collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were planned to be collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was planned to be collected on Day 16).

Time frame:
On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

No measurements were reported for this outcome.

PrimaryPercent Change From Baseline for Lipid Metabolism: Apolipoprotein A1 and Apolipoprotein B100 at Day 14

Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was the closest scheduled value prior to dosing. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.

Time frame:
Baseline and Day 14
Reported as:
Mean · Percent change
Percent Change From Baseline for Lipid Metabolism: Apolipoprotein A1 and Apolipoprotein B100 at Day 14
Percent changeAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 10 mg + PlaceboAtorvastatin 10 mg + Ezetimibe 10 mgAtorvastatin 80 mg + GSK1292263 800 mgAtorvastatin 80 mg + PlaceboGSK1292263 100 mgGSK1292263 300 mgGSK1292263 800 mgPlacebo
Apolipoprotein A1, 24 hours-1.93 ± 27.152-8.72 ± 31.7914.17 ± 38.410-7.19 ± 27.383-3.88 ± 26.818-1.00 ± 35.805-5.81 ± 47.8003.76 ± 41.28129.90 ± 99.331-0.15 ± 39.226-0.18 ± 49.478
Apolipoprotein B100, 24 hours2.85 ± 31.217-17.93 ± 19.839-22.22 ± 20.393-5.03 ± 19.932-15.49 ± 13.681-27.08 ± 14.1324.25 ± 27.890-10.21 ± 22.072-7.62 ± 23.573-10.95 ± 23.811-2.39 ± 15.932
Statistical analysis
  • Atorvastatin 10 mg + GSK1292263 100 mg vs Placebo · Mean difference (net): 5.473 · 95% CI -15.7096 to 26.6553Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 300 mg vs Placebo · Mean difference (net): -0.598 · 95% CI -21.7840 to 20.5888Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): 11.906 · 95% CI -9.3489 to 33.1602Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + Ezetimibe 10 mg vs Placebo · Mean difference (net): 3.671 · 95% CI -16.9957 to 24.3384Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 80 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): 4.618 · 95% CI -28.2069 to 37.4425Statistical analysis was performed using LS mean value of Atorvastatin
  • GSK1292263 100 mg vs Placebo · Mean difference (net): 7.713 · 95% CI -17.0405 to 39.8527Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 300 mg vs Placebo · Mean difference (net): 1.934 · 95% CI -21.0153 to 31.5504Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 800 mg vs Placebo · Mean difference (net): -2.466 · 95% CI -23.7517 to 24.7608Statistical analysis was performed using LS mean value of GSK1292263
  • Atorvastatin 10 mg + GSK1292263 100 mg vs Placebo · Mean difference (net): 13.743 · 95% CI -3.2460 to 33.7161Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 300 mg vs Placebo · Mean difference (net): -7.428 · 95% CI -21.3243 to 8.9224Statistical analysis was performed using LS mean value Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): -13.960 · 95% CI -26.8137 to 1.1513Statistical analysis was performed using LS mean value Atorvastatin
  • Atorvastatin 10 mg + Ezetimibe 10 mg vs Placebo · Mean difference (net): -2.903 · 95% CI -16.6557 to 13.1191Statistical analysis was performed using LS mean value Atorvastatin
  • Atorvastatin 80 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): -28.231 · 95% CI -45.1045 to -11.3579Statistical analysis was performed using LS mean value Atorvastatin
  • GSK1292263 100 mg vs Placebo · Mean difference (net): -6.100 · 95% CI -23.5021 to 11.3014Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 300 mg vs Placebo · Mean difference (net): -8.490 · 95% CI -25.2721 to 8.2918Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 800 mg vs Placebo · Mean difference (net): -9.687 · 95% CI -26.0247 to 6.6498Statistical analysis was performed using LS mean value of GSK1292263
PrimaryPercent Change From Baseline in Lipid Metabolism: Apolipoprotein E at Day 14 (24 Hours)

Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was the closest scheduled value prior to dosing. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.

Time frame:
Baseline and Day 14
Reported as:
Mean · Perecent change
Percent Change From Baseline in Lipid Metabolism: Apolipoprotein E at Day 14 (24 Hours)
Perecent changeAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 10 mg + PlaceboAtorvastatin 10 mg + Ezetimibe 10 mgAtorvastatin 80 mg + GSK1292263 800 mgAtorvastatin 80 mg + PlaceboGSK1292263 100 mgGSK1292263 300 mgGSK1292263 800 mgPlacebo
Percent Change From Baseline in Lipid Metabolism: Apolipoprotein E at Day 14 (24 Hours)-21.97 ± 16.373-3.92 ± 29.382-31.41 ± 17.36934.28 ± 141.042-12.27 ± 42.191-13.19 ± 19.202-13.41 ± 30.6131.35 ± 46.155-21.98 ± 37.910-33.75 ± 16.915-1.58 ± 36.044
Statistical analysis
  • Atorvastatin 10 mg + GSK1292263 100 mg vs Placebo · Mean difference (net): -19.471 · 95% CI -47.9323 to 3.2020Statistical analysis was performed using LS mean value Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 300 mg vs Placebo · Mean difference (net): -5.910 · 95% CI -38.1027 to 25.3126Statistical analysis was performed using LS mean value Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): -25.985 · 95% CI -45.5492 to 1.8605Statistical analysis was performed using LS mean value Atorvastatin
  • Atorvastatin 10 mg + Ezetimibe 10 mg vs Placebo · Mean difference (net): -16.697 · 95% CI -45.0846 to 13.3024Statistical analysis was performed using LS mean value Atorvastatin
  • Atorvastatin 80 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): -6.036 · 95% CI -27.2281 to 15.1569Statistical analysis was performed using LS mean value of Atorvastatin
  • GSK1292263 100 mg vs Placebo · Mean difference (net): 0.198 · 95% CI -24.2901 to 32.6057Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 300 mg vs Placebo · Mean difference (net): -22.117 · 95% CI -40.4767 to 1.9060Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 800 mg vs Placebo · Mean difference (net): -32.798 · 95% CI -48.3842 to -12.5064Statistical analysis was performed using LS mean value of GSK1292263
PrimaryPercent Change From Baseline in Lipid Metabolism: High Density Lipids Cholesterol (HDLc), Low Density Lipids Cholesterol (LDLc), Tryglycerides, Non-HDLc and Total Cholesterol at Day 14 (24 Hours)

Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was the closest scheduled value prior to dosing. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.

Time frame:
Baseline and Day 14
Reported as:
Mean · Percent change
Percent Change From Baseline in Lipid Metabolism: High Density Lipids Cholesterol (HDLc), Low Density Lipids Cholesterol (LDLc), Tryglycerides, Non-HDLc and Total Cholesterol at Day 14 (24 Hours)
Percent changeAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 10 mg + PlaceboAtorvastatin 10 mg + Ezetimibe 10 mgAtorvastatin 80 mg + GSK1292263 800 mgAtorvastatin 80 mg + PlaceboGSK1292263 100 mgGSK1292263 300 mgGSK1292263 800 mgPlacebo
HDLc7.50 ± 13.63914.97 ± 7.70031.09 ± 11.966-0.03 ± 14.7146.03 ± 11.85026.22 ± 15.8404.50 ± 10.9369.17 ± 10.2779.76 ± 17.16018.95 ± 12.847-1.37 ± 7.140
LDLc-6.80 ± 14.522-10.01 ± 21.231-24.09 ± 18.017-0.37 ± 19.794-24.81 ± 12.317-18.63 ± 16.53415.01 ± 59.194-10.24 ± 11.438-11.86 ± 16.873-19.94 ± 10.6880.77 ± 11.347
Triglyceides-18.67 ± 16.693-15.98 ± 24.307-32.81 ± 21.24910.70 ± 32.177-10.44 ± 21.628-21.39 ± 28.1902.27 ± 17.025-3.95 ± 23.855-30.84 ± 11.753-34.66 ± 21.19718.90 ± 18.225
Non-HDLc-9.53 ± 8.502-11.67 ± 18.562-26.59 ± 13.7422.08 ± 16.176-21.19 ± 11.920-21.88 ± 11.157-0.94 ± 8.977-9.32 ± 13.107-17.02 ± 12.376-22.62 ± 10.2903.17 ± 9.283
Total cholesterol-5.17 ± 9.210-3.61 ± 12.355-10.31 ± 8.9120.89 ± 12.671-14.23 ± 9.640-5.52 ± 7.7211.09 ± 6.724-5.81 ± 10.091-12.06 ± 9.650-14.05 ± 7.6142.18 ± 7.900
Statistical analysis
  • Atorvastatin 10 mg + GSK1292263 100 mg vs Placebo · Mean difference (net): 5.101 · 95% CI -4.5469 to 14.7495Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 300 mg vs Placebo · Mean difference (net): 12.273 · 95% CI 2.5937 to 21.9532Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): 28.833 · 95% CI 18.9550 to 38.7102Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + Ezetimibe 10 mg vs Placebo · Mean difference (net): 3.701 · 95% CI -5.5562 to 12.9578Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 80 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): 20.946 · 95% CI 8.6120 to 33.2810Statistical analysis was performed using LS mean value of Atorvastatin
  • GSK1292263 100 mg vs Placebo · Median difference (net): 10.561 · 95% CI -0.9675 to 22.0898Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 300 mg vs Placebo · Mean difference (net): 11.122 · 95% CI -0.2902 to 22.5351Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 800 mg vs Placebo · Mean difference (net): 20.689 · 95% CI 9.7527 to 31.6262Statistical analysis was performed using LS mean value of GSK1292263
  • Atorvastatin 10 mg + GSK1292263 100 mg vs Placebo · Mean difference (net): -4.549 · 95% CI -18.7750 to 9.6768Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 300 mg vs Placebo · Mean difference (net): -10.337 · 95% CI -24.4549 to 3.7803Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): -21.317 · 95% CI -36.0144 to -6.6190Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + Ezetimibe 10 mg vs Placebo · Mean difference (net): -20.173 · 95% CI -34.2710 to -6.0755Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 80 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): -25.472 · 95% CI -49.3385 to -8.1558Statistical analysis was performed using LS mean value of Atorvastatin
  • GSK1292263 100 mg vs Placebo · Mean difference (net): -12.128 · 95% CI -23.3049 to -0.9514Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 300 mg vs Placebo · Mean difference (net): -15.798 · 95% CI -27.1364 to -4.4589Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 800 mg vs Placebo · Mean difference (net): -21.789 · 95% CI -32.3413 to -11.2372Statistical analysis was performed using LS mean value of GSK1292263
  • Atorvastatin 10 mg + GSK1292263 100 mg vs Placebo · Mean difference (net): -22.498 · 95% CI -38.4460 to -2.4169Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 300 mg vs Placebo · Mean difference (net): -23.781 · 95% CI -39.1603 to -4.5130Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): -39.923 · 95% CI -52.3394 to -24.2717Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + Ezetimibe 10 mg vs Placebo · Mean difference (net): -17.444 · 95% CI -33.5020 to 2.4910Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 80 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): -21.781 · 95% CI -40.2960 to -3.2667Statistical analysis was performed using LS mean value of Atorvastatin
  • GSK1292263 100 mg vs Placebo · Mean difference (net): -21.421 · 95% CI -38.3519 to -4.4911Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 300 mg vs Placebo · Mean difference (net): -46.361 · 95% CI -63.4650 to -29.2561Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 800 mg vs Placebo · Mean difference (net): -54.843 · 95% CI -70.7854 to -38.9007Statistical analysis was performed using LS mean value of GSK1292263
  • Atorvastatin 10 mg + GSK1292263 100 mg vs Placebo · Mean difference (net): -9.756 · 95% CI -21.7561 to 2.2448Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 300 mg vs Placebo · Mean difference (net): -14.014 · 95% CI -25.7497 to -2.2787Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): -27.675 · 95% CI -39.8454 to -15.5045Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + Ezetimibe 10 mg vs Placebo · Mean difference (net): -20.937 · 95% CI -32.6057 to -9.2690Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 80 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): -21.702 · 95% CI -29.0346 to -14.3696Statistical analysis was performed using LS mean value of Atorvastatin
  • GSK1292263 100 mg vs Placebo · Mean difference (net): -13.180 · 95% CI -23.0636 to -3.2961Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 300 mg vs Placebo · Mean difference (net): -22.151 · 95% CI -31.9420 to -12.3605Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 800 mg vs Placebo · Mean difference (net): -26.948 · 95% CI -36.2874 to -17.6092Statistical analysis was performed using LS mean value of GSK1292263
  • Atorvastatin 10 mg + GSK1292263 100 mg vs Placebo · Mean difference (net): -3.904 · 95% CI -11.8484 to 4.0400Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 300 mg vs Placebo · Mean difference (net): -6.437 · 95% CI -14.3460 to 1.4722Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): -10.294 · 95% CI -18.3923 to -2.1960Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + Ezetimibe 10 mg vs Placebo · Mean difference (net): -12.065 · 95% CI -19.7688 to -4.3609Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 80 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): -7.941 · 95% CI -13.9778 to -1.9039Statistical analysis was performed using LS mean value of Atorvastatin
  • GSK1292263 100 mg vs Placebo · Mean difference (net): -8.384 · 95% CI -15.9023 to -0.8660Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 300 mg vs Placebo · Mean difference (net): -15.700 · 95% CI -23.1404 to -8.2592Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 800 mg vs Placebo · Mean difference (net): -16.728 · 95% CI -23.8395 to -9.6161
PrimaryPercent Change From Baseline in Lipid Metabolism: LDL/HDL Ratio at Day 14 (24 Hours)

Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was the closest scheduled value prior to dosing. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.

Time frame:
Baseline and Day 14
Reported as:
Mean · Percent change
Percent Change From Baseline in Lipid Metabolism: LDL/HDL Ratio at Day 14 (24 Hours)
Percent changeAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 10 mg + PlaceboAtorvastatin 10 mg + Ezetimibe 10 mgAtorvastatin 80 mg + GSK1292263 800 mgAtorvastatin 80 mg + PlaceboGSK1292263 100 mgGSK1292263 300 mgGSK1292263 800 mgPlacebo
Percent Change From Baseline in Lipid Metabolism: LDL/HDL Ratio at Day 14 (24 Hours)-12.25 ± 14.784-21.12 ± 20.549-41.61 ± 14.2480.94 ± 20.727-28.69 ± 11.963-34.35 ± 16.04710.84 ± 56.487-16.78 ± 15.615-17.63 ± 23.327-32.01 ± 11.2872.55 ± 12.789
Statistical analysis
  • Atorvastatin 10 mg + GSK1292263 100 mg vs Placebo · Mean difference (net): -12.123 · 95% CI -26.6276 to 2.3814Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 300 mg vs Placebo · Mean difference (net): -21.630 · 95% CI -35.9419 to -7.3181Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): -41.506 · 95% CI -56.3924 to -26.6205Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + Ezetimibe 10 mg vs Placebo · Mean difference (net): -28.041 · 95% CI -42.2554 to -13.8263Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 80 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): -29.293 · 95% CI -51.5654 to -12.4042Statistical analysis was performed using LS mean value of Atorvastatin
  • GSK1292263 100 mg vs Placebo · Mean difference (net): -20.042 · 95% CI -34.8358 to -5.2472Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 300 mg vs Placebo · Mean difference (net): -21.903 · 95% CI -36.6155 to -7.1913Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 800 mg vs Placebo · Mean difference (net): -35.735 · 95% CI -49.7220 to -21.7485Statistical analysis was performed using LS mean value of GSK1292263
PrimaryWeighted Mean Area Under Concentration Curve From 0 to 24 Hours (AUC [0-24]) Change From Baseline for Triglycerides at Day 14

Blood samples were collected fasting on Days 1 (pre-dose), 7 and 15 prior to checkout (24 hours post-dose), and at Follow-up. When this results in multiple samples at the same time point, only one sample will be collected (example, when 24 hours post-dose = pre-dose (time 0) for the next dose). Baseline was Day -1 value. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. If either the Baseline or post-randomization value is missing, the change from Baseline was set to missing as well. Percent change from Baseline was calculated as the change from Baseline divided by the Baseline value then multiplied by 100.

Time frame:
Baseline and Day 14
Reported as:
Geometric mean · millimoles per liter
Weighted Mean Area Under Concentration Curve From 0 to 24 Hours (AUC [0-24]) Change From Baseline for Triglycerides at Day 14
millimoles per literAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 10 mg + PlaceboAtorvastatin 10 mg + Ezetimibe 10 mgAtorvastatin 80 mg + GSK1292263 800 mgAtorvastatin 80 mg + PlaceboGSK1292263 100 mgGSK1292263 300 mgGSK1292263 800 mgPlacebo
Weighted Mean Area Under Concentration Curve From 0 to 24 Hours (AUC [0-24]) Change From Baseline for Triglycerides at Day 140.13341 ± -167.3950.30812 ± -360.9660.12845 ± -68.42940.25228 ± 477.03800.09060 ± -146.9560.04974 ± -76.19730.20164 ± -485.9610.30543 ± -159.0120.37442 ± -111.8180.13079 ± -115.2100.28863 ± 93.3050
Statistical analysis
  • Atorvastatin 10 mg + GSK1292263 100 mg vs Placebo · Mean difference (net): -0.409 · 95% CI -1.0123 to 0.1942Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 300 mg vs Placebo · Mean difference (net): -0.296 · 95% CI -0.9063 to 0.3141Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): -0.811 · 95% CI -1.4125 to -0.2098Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 10 mg + Ezetimibe 10 mg vs Placebo · Mean difference (net): -0.422 · 95% CI -0.9831 to 0.1394Statistical analysis was performed using LS mean value of Atorvastatin
  • Atorvastatin 80 mg + GSK1292263 800 mg vs Placebo · Mean difference (net): -0.384 · 95% CI -0.6009 to -0.1669Statistical analysis was performed using LS mean value of Atorvastatin
  • GSK1292263 100 mg vs Placebo · Mean difference (net): -0.648 · 95% CI -1.1657 to -0.1302Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 300 mg vs Placebo · Mean difference (net): -0.782 · 95% CI -1.2804 to -0.2844Statistical analysis was performed using LS mean value of GSK1292263
  • GSK1292263 800 mg vs Placebo · Mean difference (net): -0.884 · 95% CI -1.3652 to -0.4026Statistical analysis was performed using LS mean value of GSK1292263
SecondaryCmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A

Serial blood samples for the determination of the PK for atorvastatin metabolites on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin metabolites on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).

Time frame:
On Day -1 at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose. on Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose.
Reported as:
Geometric mean · nanograms per milliliter
Cmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A
nanograms per milliliterAtorvastatin 80 mg + GSK1292263 800 mg
Day -117.521 ± 66.1066
Day 115.535 ± 48.2576
Day 1421.271 ± 30.4382
SecondaryCmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)

For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin metabolites were collected on Day -1 and for atorvastatin metabolites on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).

Time frame:
On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Reported as:
Geometric mean · nanograms per milliliter
Cmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)
nanograms per milliliterAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 10 mg + PlaceboAtorvastatin 10 mg + Ezetimibe 10 mgAtorvastatin 80 mg + GSK1292263 800 mgAtorvastatin 80 mg + Placebo
Day -11.298 ± 37.36151.388 ± 42.81630.947 ± 39.39470.952 ± 63.18141.185 ± 119.967526.106 ± 102.261721.149 ± 39.5618
Day 11.073 ± 19.33291.217 ± 36.05971.048 ± 33.91651.028 ± 67.06301.234 ± 44.767919.991 ± 71.244226.400 ± 44.9589
Day 140.634 ± 12.55451.152 ± 53.42561.084 ± 49.90970.869 ± 62.01121.349 ± 42.020322.645 ± 75.716127.236 ± 68.7891
SecondaryTmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A

Serial blood samples for the determination of the PK for atorvastatin metabolites on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin metabolites on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).

Time frame:
On Day -1 at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose. on Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose.
Reported as:
Median · hours
Tmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A
hoursAtorvastatin 80 mg + GSK1292263 800 mg
Day -13.000 (1.00 to 4.00)
Day 14.000 (4.00 to 6.00)
Day 142.500 (2.00 to 4.00)
SecondaryTmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)

For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin metabolites were collected on Day -1 and for atorvastatin metabolites on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).

Time frame:
On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose and on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Reported as:
Median · hours
Tmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)
hoursAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 10 mg + PlaceboAtorvastatin 10 mg + Ezetimibe 10 mgAtorvastatin 80 mg + GSK1292263 800 mgAtorvastatin 80 mg + Placebo
Day -14.500 (1.00 to 6.08)4.000 (3.00 to 8.00)5.000 (2.00 to 8.02)4.000 (3.00 to 8.00)4.000 (4.00 to 6.00)3.992 (1.00 to 6.00)3.000 (1.00 to 4.00)
Day 16.000 (6.00 to 6.00)6.000 (4.00 to 8.00)4.000 (2.00 to 14.10)4.000 (1.50 to 10.00)4.000 (2.00 to 6.00)4.000 (1.50 to 6.08)3.000 (0.50 to 6.02)
Day 146.000 (2.83 to 8.00)4.000 (3.00 to 14.00)4.025 (3.00 to 6.08)5.000 (1.50 to 14.02)6.000 (3.00 to 6.00)4.000 (1.50 to 6.00)3.983 (1.00 to 6.05)
SecondaryAUC (0-24) of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A

Serial blood samples for the determination of the PK for atorvastatin metabolites on Day -1 was collected at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose (24 hour sample Day -1 = 0 hour sample Day 1). Serial blood samples for the determination of the PK for atorvastatin metabolites on Days 1 and 14 will be collected at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose (no 48h sample on Day 1).

Time frame:
On Day -1 at immediately pre-morning dose=pre-breakfast (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 24 hours post-morning dose. on Days 1 and 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hour post-morning dose.
Reported as:
Geometric mean · nanograms hour per milliliter
AUC (0-24) of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A
nanograms hour per milliliterAtorvastatin 80 mg + GSK1292263 800 mg
Day -1119.66 ± 72.635
Day 1127.70 ± 49.098
Day 14139.78 ± 47.491
SecondaryAUC (0-24) of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)

For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin metabolites were collected on Day -1 and for atorvastatin metabolites on Days 1 and 14. Blood samples for PK were collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16).

Time frame:
On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose
Reported as:
Geometric mean · nanograms hour per milliliter
AUC (0-24) of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)
nanograms hour per milliliterAtorvastatin 10 mg + GSK1292263 100 mgAtorvastatin 10 mg + GSK1292263 300 mgAtorvastatin 10 mg + GSK1292263 800 mgAtorvastatin 10 mg + PlaceboAtorvastatin 10 mg + Ezetimibe 10 mgAtorvastatin 80 mg + GSK1292263 800 mgAtorvastatin 80 mg + Placebo
Day -116.72 ± 19.50920.25 ± 47.04714.37 ± 48.59812.38 ± 74.28612.41 ± 53.128163.16 ± 73.666133.96 ± 36.159
Day 116.02 ± 9.35518.28 ± 40.61114.89 ± 33.54113.60 ± 78.37915.10 ± 26.181146.23 ± 55.353150.41 ± 37.440
Day 1410.07 ± 12.34616.54 ± 37.12313.82 ± 43.13112.03 ± 63.14518.18 ± 36.758144.23 ± 58.954156.41 ± 42.286
SecondaryTrough Concentration of Atorvastatin Metabolite (2-Hydroxyatorvastatin)

For co-dosing arms, serial blood samples for the determination of the PK of atorvastatin metabolites were supposed to collected on Day -1 and for atorvastatin metabolites on Days 1 and 14. Blood samples for PK were supposed to collected on Days -1 (co-dosing arms only) and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. Blood samples for PK were supposed to collected on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose (48 hour PK sample was collected on Day 16). However no data was collected.

Time frame:
On Days -1 and 1 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, and 24 hours post-morning dose. on Day 14 at immediately pre-morning dose (time 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14, 24 and 48 hours post-morning dose

No measurements were reported for this outcome.

Adverse events

Collected over All AEs and SAEs were collected up to follow-up visit. For Part A- up to Day 26, for Part B (washout)- up to Day 28, for Part B (run-in)- up to day up to day 28 and Part B (treatment)- up to Day 26. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
80 mg Atorvastatin + 800 mg GSK1292263 (Part A)0/4 (0%)0/4 (0%)0/4 (0%)
800 mg GSK1292263 (Part A)0/2 (0%)0/2 (0%)2/2 (100%)
Pre-treatment (Part B)0/281 (0%)0/281 (0%)14/281 (5%)
Washout (Part B)0/281 (0%)0/281 (0%)37/281 (13.2%)
Atorvastatin 10 mg (Part B Run-in)0/62 (0%)0/62 (0%)19/62 (30.6%)
Atorvastatin 80 mg (Part B Run-in)0/27 (0%)0/27 (0%)8/27 (29.6%)
Atorvastatin 10 mg + GSK1292263 100 mg (Part B Treatment)0/11 (0%)0/11 (0%)6/11 (54.5%)
Atorvastatin 10 mg + GSK1292263 300 mg (Part B Treatment)0/11 (0%)0/11 (0%)2/11 (18.2%)
Atorvastatin 10 mg + GSK1292263 800 mg (Part B Treatment)0/11 (0%)0/11 (0%)3/11 (27.3%)
Atorvastatin 10 mg + Placebo (Part B Treatment)0/12 (0%)0/12 (0%)3/12 (25%)
Atorvastatin 10 mg + Ezetimibe 10 mg (Part B Treatment)0/13 (0%)0/13 (0%)4/13 (30.8%)
Atorvastatin 80 mg + GSK1292263 800 mg (Part B Treatment)0/12 (0%)0/12 (0%)6/12 (50%)
Atorvastatin 80 mg + Placebo (Part B Treatment)0/13 (0%)0/13 (0%)4/13 (30.8%)
GSK1292263 100 mg (Part B Treatment)0/11 (0%)0/11 (0%)5/11 (45.5%)
GSK1292263 300 mg (Part B Treatment)0/12 (0%)0/12 (0%)7/12 (58.3%)
GSK1292263 800 mg (Part B Treatment)0/13 (0%)0/13 (0%)8/13 (61.5%)
Placebo (Part B Treatment)0/11 (0%)0/11 (0%)4/11 (36.4%)
Most frequent other events
Showing 10 of 94
Most frequent other events
Event80 mg Atorvastatin + 800 mg GSK1292263 (Part A)800 mg GSK1292263 (Part A)Pre-treatment (Part B)Washout (Part B)Atorvastatin 10 mg (Part B Run-in)Atorvastatin 80 mg (Part B Run-in)Atorvastatin 10 mg + GSK1292263 100 mg (Part B Treatment)Atorvastatin 10 mg + GSK1292263 300 mg (Part B Treatment)Atorvastatin 10 mg + GSK1292263 800 mg (Part B Treatment)Atorvastatin 10 mg + Placebo (Part B Treatment)Atorvastatin 10 mg + Ezetimibe 10 mg (Part B Treatment)Atorvastatin 80 mg + GSK1292263 800 mg (Part B Treatment)Atorvastatin 80 mg + Placebo (Part B Treatment)GSK1292263 100 mg (Part B Treatment)GSK1292263 300 mg (Part B Treatment)GSK1292263 800 mg (Part B Treatment)Placebo (Part B Treatment)
DiarrhoeaGastrointestinal disorders0/41/20/2811/2810/620/270/111/110/110/120/130/120/130/111/120/131/11
VomitingGastrointestinal disorders0/41/20/2810/2810/620/270/110/110/110/120/130/120/130/111/120/130/11
PhlebitisVascular disorders0/41/20/2810/2810/620/270/110/110/110/120/130/120/130/110/120/130/11
NauseaGastrointestinal disorders0/40/20/2812/2813/620/270/110/111/110/120/130/120/130/114/120/130/11
HeadacheNervous system disorders0/40/20/2817/2817/621/273/111/111/110/122/132/123/132/111/122/132/11
RashSkin and subcutaneous tissue disorders0/40/20/2810/2810/620/272/110/110/110/120/130/120/130/110/121/130/11
ContusionInjury, poisoning and procedural complications0/40/20/2811/2810/622/270/110/110/111/120/130/120/130/112/120/130/11
ConstipationGastrointestinal disorders0/40/20/2810/2811/620/270/110/110/110/120/131/121/130/112/121/130/11
DizzinessNervous system disorders0/40/20/2810/2810/620/270/110/110/110/120/132/121/130/110/120/130/11
Upper respiratory tract infectionInfections and infestations0/40/25/2814/2811/621/270/110/110/110/120/130/120/130/110/120/131/11

Baseline characteristics

One participant was withdrawn prior to washout period. 34 participants did not complete washout phase. 111 participants did not qualify to continue in the study after completing the Washout Phase. 6 participants were withdrawn during run-in phase and 3 participants were withdrawn during treatment phase.

Age, Continuous
Age, Continuous(Years)Part APart BTotal
Mean49.2 ± 5.34—49.2 ± 5.34
Age, Continuous
Age, Continuous(Years)Part APart BTotal
Mean—57.7 ± 9.9757.7 ± 9.97
Sex: Female, Male
Sex: Female, Male(Participants)Part APart BTotal
Female0152152
Male6129135
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part APart BTotal
African American/African Heritage13233
American Indian or Alaska Native011
Asian - Central/South Asian Heritage022
Asian - Japanese Heritage022
Asian - South East Asian Heritage011
Native Hawaiian or other Pacific Islander011
White - Arabic/North African Heritage077
White - White/Caucasian/European Heritage5230235
White - Mixed Race011
Mixed Race033
08

Study locations

21 sites
  • GSK Investigational Site
    Anniston, Alabama 36207, United States
  • GSK Investigational Site
    Chula Vista, California 91910, United States
  • GSK Investigational Site
    Stockton, California 95204, United States
  • GSK Investigational Site
    Jacksonville, Florida 32216, United States
  • GSK Investigational Site
    Miami, Florida 33169, United States
  • GSK Investigational Site
    Miami, Florida 33183, United States
  • GSK Investigational Site
    Port Orange, Florida 32127, United States
  • GSK Investigational Site
    Saint Petersburg, Florida 33709, United States
  • GSK Investigational Site
    Chicago, Illinois 60607, United States
  • GSK Investigational Site
    Chicago, Illinois 60610, United States
  • GSK Investigational Site
    Louisville, Kentucky 40213, United States
  • GSK Investigational Site
    Kalamazoo, Michigan 49007, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55430, United States
  • GSK Investigational Site
    Berlin, New Jersey 08009, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45246, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • GSK Investigational Site
    Eugene, Oregon 97404, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    San Antonio, Texas 78205, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Renton, Washington 98057, United States
09

References and documents

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2010 to primary completion in Jun 2011, 9 months.

Results were first posted in Nov 2017, 6 years 4 months after primary completion. A results delay was requested in Apr 2015.

Of 35 industry-sponsored phase 2 interventional studies under Dyslipidemias, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 9 months is below that.

Counting every sponsor, half of 43 studies reached it within 13 months; a quarter within 7 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2010
First posted
Oct 11, 2010
StartActual
Sep 14, 2010
Primary completionActual
Jun 29, 2011
CompletionActual
Jun 29, 2011
Results delay requested
Apr 27, 2015
Results first posted
Nov 8, 2017
Last update
Jul 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01218204
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 11, 2010
Start date
Sep 14, 2010
Primary completion
Jun 29, 2011
Completion
Jun 29, 2011
Results posted
Nov 8, 2017
Last update
Jul 16, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atorvastatin · Gsk-1292263

Start the discussion